Madrigal Pharmaceuticals (MDGL) News Today $308.44 +15.03 (+5.12%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Geode Capital Management LLC Boosts Stock Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Geode Capital Management LLC boosted its position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 1.5% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 405,655 shares of the biopharmaceutical compaDecember 20 at 4:25 AM | marketbeat.comMadrigal Pharmaceuticals' SWOT analysis: rezdiffra launch key to stock's futureDecember 19 at 8:29 PM | uk.investing.comWellington Management Group LLP Buys New Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Wellington Management Group LLP purchased a new stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 9,031 shares of the biopharmaceutDecember 19 at 3:33 AM | marketbeat.comNovo Nordisk: A New Boost for GLP-1 Sales on the Horizon (MDGL)Novo Nordisk A/S is moving closer to adding more sales for its blockbuster GLP-1 drug semaglutide to treat a chronic liver disease.December 18 at 10:38 AM | marketbeat.comBarclays PLC Raises Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Barclays PLC boosted its stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 159.9% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 40,279 shares of the biopharmaceutical company's stock after buying anDecember 18 at 4:08 AM | marketbeat.comY Intercept Hong Kong Ltd Acquires Shares of 1,736 Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Y Intercept Hong Kong Ltd bought a new stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 1,736 shares of the biopharmaceutical company's stock, valued at approxDecember 17, 2024 | marketbeat.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives $347.33 Average Price Target from AnalystsDecember 16, 2024 | americanbankingnews.comState Street Corp Has $188.40 Million Stock Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)State Street Corp boosted its position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 19.2% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 887,752 shares of the biopharmaceutical company's stockDecember 13, 2024 | marketbeat.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Average Recommendation of "Moderate Buy" by BrokeragesMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) has been given an average rating of "Moderate Buy" by the thirteen analysts that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have assignedDecember 13, 2024 | marketbeat.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLCUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 9.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional inDecember 12, 2024 | marketbeat.com4,881 Shares in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Bought by XTX Topco LtdXTX Topco Ltd bought a new position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 4,881 shares of the biopharmaceutical company's stock, valuDecember 10, 2024 | marketbeat.comBNP Paribas Financial Markets Has $2.07 Million Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)BNP Paribas Financial Markets increased its position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 97.1% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 9,767 shares of the biopharmaceutical company's stock after buying an additDecember 7, 2024 | marketbeat.comInsider Selling: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Director Sells 3,600 Shares of StockDecember 6, 2024 | insidertrades.comThe Manufacturers Life Insurance Company Has $6.36 Million Stock Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)The Manufacturers Life Insurance Company lessened its stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 16.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 29,957 shares of the biopharmaceuDecember 6, 2024 | marketbeat.comMadrigal Pharmaceuticals price target raised to $427 from $415 at JMP SecuritiesDecember 5, 2024 | markets.businessinsider.comRTW Investments LP Acquires 77,825 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)RTW Investments LP boosted its holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 4.1% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,993,687 shares of the biopharmaceutical company'sDecember 5, 2024 | marketbeat.comCinctive Capital Management LP Invests $1.08 Million in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Cinctive Capital Management LP bought a new stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 5,074 shares of theDecember 4, 2024 | marketbeat.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Sold by Fmr LLCFmr LLC reduced its stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 0.7% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 783,545 shares of the biopharmaceutical company's stock after seDecember 4, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Increases Stock Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Charles Schwab Investment Management Inc. increased its position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 7.0% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 147,970 shares of the biopharDecember 4, 2024 | marketbeat.comMartingale Asset Management L P Takes Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Martingale Asset Management L P acquired a new stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 5,764 shares of the biopharmaceutical company'December 2, 2024 | marketbeat.comErste Asset Management GmbH Takes $49.75 Million Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Erste Asset Management GmbH purchased a new stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 234,400 sDecember 1, 2024 | marketbeat.comBraidwell LP Makes New $39.01 Million Investment in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Braidwell LP purchased a new position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 183,818 shares of the biopharmaceutical cNovember 29, 2024 | marketbeat.comVestal Point Capital LP Buys Shares of 30,000 Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Vestal Point Capital LP bought a new position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 30,000 shares of the biopharmaceutical company's stocNovember 29, 2024 | marketbeat.com1,852 Shares in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Purchased by Blueshift Asset Management LLCBlueshift Asset Management LLC purchased a new stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 1,852 shares of the biopharmaceutical company's stock, valued aNovember 29, 2024 | marketbeat.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Director Sells $1,191,020.00 in StockNovember 28, 2024 | insidertrades.comAdvantage Alpha Capital Partners LP Acquires New Stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Advantage Alpha Capital Partners LP bought a new position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 1,643 shares of the biopharmaceutical company's sNovember 27, 2024 | marketbeat.com6,032 Shares in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Purchased by Intech Investment Management LLCIntech Investment Management LLC purchased a new stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 6,032 shares of the biopharmaceutical company's stock, valued aNovember 27, 2024 | marketbeat.comEagle Asset Management Inc. Makes New Investment in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Eagle Asset Management Inc. purchased a new stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 32,396 shares of the biopharmaceutical company's stock, valued at approxiNovember 25, 2024 | marketbeat.com3 Reasons Why Buying Madrigal Pharmaceuticals Today Is a Wise MoveNovember 23, 2024 | fool.comConnor Clark & Lunn Investment Management Ltd. Sells 10,979 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Connor Clark & Lunn Investment Management Ltd. reduced its position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 13.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 72,083 shares of thNovember 21, 2024 | marketbeat.comMadrigal Pharmaceuticals price target raised to $400 from $350 at OppenheimerNovember 21, 2024 | markets.businessinsider.comMadrigal Pharmaceuticals (MDGL) Receives a Buy from TD CowenNovember 20, 2024 | markets.businessinsider.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Given "Neutral" Rating at Cantor FitzgeraldCantor Fitzgerald reiterated a "neutral" rating on shares of Madrigal Pharmaceuticals in a research note on Wednesday.November 20, 2024 | marketbeat.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Average Recommendation of "Moderate Buy" from AnalystsShares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the thirteen analysts that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two hNovember 18, 2024 | marketbeat.comMadrigal Pharmaceuticals gains amid takeover speculationNovember 15, 2024 | msn.com1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or MoreNovember 10, 2024 | fool.comMadrigal Pharmaceuticals Engages with Investors at Key ConferencesNovember 9, 2024 | msn.comFiera Capital Corp Reduces Stock Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Fiera Capital Corp cut its position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 3.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 111,880 shares of the biopharmaceutical comNovember 9, 2024 | marketbeat.comB. Riley Has Positive Estimate for MDGL FY2024 EarningsMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) - Analysts at B. Riley boosted their FY2024 earnings estimates for Madrigal Pharmaceuticals in a report issued on Monday, November 4th. B. Riley analyst M. Mamtani now expects that the biopharmaceutical company will earn ($23.09) per sharNovember 7, 2024 | marketbeat.comMadrigal Pharmaceuticals price target raised to $236 from $194 at B. RileyNovember 6, 2024 | markets.businessinsider.comMadrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor ConferencesNovember 6, 2024 | globenewswire.comEquities Analysts Issue Forecasts for MDGL Q1 EarningsMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) - B. Riley issued their Q1 2025 EPS estimates for shares of Madrigal Pharmaceuticals in a report released on Monday, November 4th. B. Riley analyst M. Mamtani forecasts that the biopharmaceutical company will post earnings per share of ($November 6, 2024 | marketbeat.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Director Sells $1,504,700.00 in StockNovember 6, 2024 | insidertrades.comB. Riley Forecasts Strong Price Appreciation for Madrigal Pharmaceuticals (NASDAQ:MDGL) StockB. Riley raised their target price on Madrigal Pharmaceuticals from $194.00 to $236.00 and gave the stock a "neutral" rating in a research note on Tuesday.November 5, 2024 | marketbeat.comMadrigal Stock Soars 23% as NASH Drug Rezdiffra Crushes ExpectationsNovember 4, 2024 | finance.yahoo.comJefferies Keeps Their Buy Rating on Madrigal Pharmaceuticals (MDGL)November 4, 2024 | markets.businessinsider.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Sets New 1-Year High on Analyst UpgradeMadrigal Pharmaceuticals (NASDAQ:MDGL) Sets New 1-Year High on Analyst UpgradeNovember 4, 2024 | marketbeat.comEmerald Advisers LLC Reduces Stock Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Emerald Advisers LLC trimmed its holdings in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 71.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 27,265 shares of the biopharmaceuticaNovember 4, 2024 | marketbeat.comWhat is Leerink Partnrs' Forecast for MDGL FY2028 Earnings?Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) - Leerink Partnrs raised their FY2028 earnings per share (EPS) estimates for shares of Madrigal Pharmaceuticals in a note issued to investors on Thursday, October 31st. Leerink Partnrs analyst T. Smith now expects that the biopharmaceuticNovember 4, 2024 | marketbeat.comEvercore ISI Sticks to Its Buy Rating for Madrigal Pharmaceuticals (MDGL)November 3, 2024 | markets.businessinsider.com Get Madrigal Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MDGL and its competitors with MarketBeat's FREE daily newsletter. Email Address 2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (Ad)The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months. 👉[Click here to get your FREE report delivered instantly!] MDGL Media Mentions By Week MDGL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MDGL News Sentiment▼1.280.61▲Average Medical News Sentiment MDGL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MDGL Articles This Week▼78▲MDGL Articles Average Week Get Madrigal Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MDGL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Biogen News Today United Therapeutics News Today Neurocrine Biosciences News Today Incyte News Today BioMarin Pharmaceutical News Today Exact Sciences News Today Exelixis News Today Repligen News Today Halozyme Therapeutics News Today Ionis Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MDGL) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Madrigal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Madrigal Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MDGL Stock Alerts